Akeso/Summit’s Bispecific Ivonescimab Bests Keytruda In 1L NSCLC
China-Only Study But Big Implications?
Ivonescimab has shown significant and "extremely commercially meaningful" improvements in progression-free survival versus Keytruda as a first-line therapy for lung cancer in a trial in China, potentially positioning it as a new chemo-free solution for all PD-L1-positive patients in this setting.
